tocilizumab - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.07 [0.64, 1.79]< 160%4 studies (4/-)39.5 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.11 [0.59, 2.09]< 10%1 study (1/-)37.4 %lownot evaluable highimportant-
clinical improvement 1.29 [0.97, 1.71]> 160%3 studies (3/-)95.9 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
death or ventilation 1.10 [0.60, 2.01]< 19%2 studies (2/-)37.7 %some concernnot evaluable moderateimportant-

safety endpoints 00

superinfection 0.77 [0.48, 1.23]< 10%1 study (1/-)86.0 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.